In NSCLC, Longer Survival With Brigatinib Than Crizotinib

Longer progression - free survival in those with ALK - positive dz who did not previously take ALK inhibitor
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Oncology, Pulmonology, Journal, Source Type: news